Dementia and Geriatric Cognitive Disorders
Original Research Article
Free Access
Long-Term Statin Therapy and CSF Cholesterol Levels: Implications for Alzheimer’s DiseaseEvans B.A.a · Evans J.E.a · Baker S.P.c · Kane K.b · Swearer J.b · Hinerfeld D.d · Caselli R.e · Rogaeva E.f · St. George-Hyslop P.f · Moonis M.b · Pollen D.A.baProteomics and Mass Spectrometry Facility, and bDepartment of Neurology, University of Massachusetts Medical School, and cBioinformatics Unit, Information Service and Department of Cell Biology, Worcester, Mass., dJackson Laboratory, Bar Harbor, Me., and eDepartment of Neurology, Mayo Clinic, Scottsdale, Ariz., USA; fDivision of Neurology, Department of Medicine, University of Toronto and Toronto Western Hospital, Toronto, Ont., Canada
Dr. Dan Pollen Department of Neurology, University of Massachusetts Medical School 55 Lake Ave. N. Worcester, MA 01655 (USA) E-Mail pollend@ummhc.org |
|
Dement Geriatr Cogn Disord 2009;27:519–524
Abstract
Background/Aims: It is not yet established whether statins (lipophilic or hydrophilic) reduce the risk of Alzheimer’s disease and, if so, by differentially modifying brain lipid levels. Our aim was to assess changes in brain cholesterol metabolism as reflected in the cerebrospinal fluid (CSF) before and after treatment with either atorvastatin or simvastatin. Methods: We carried out a longitudinal analysis of CSF cholesterol, lathosterol and 24(S)-hydroxycholesterol before and after treatment with maximum doses of statins in 10 asymptomatic subjects, 8 of whom were heterozygous for apolipoprotein E ε4, and in 6 presymptomatic PS1 subjects. Results: Statins initially reduced CSF lathosterol cholesterol and 24(S)-hydroxycholesterol in both PS1 and non-PS1 subjects reaching a nadir at 6–7 months, followed by a return to baseline at 15 months with an overshoot at 2 years, tending to return to baseline thereafter. Conclusions: Possible long-term protective effects of statins are not likely largely related to the temporally-dependent biphasic effects of statin therapy upon the magnitude and direction of changes in CSF lipid levels and their subsequent return to baseline levels.
© 2009 S. Karger AG, Basel
References
- Saunders AM, Strittmatter WJ, Schmechel D, et al: Association of apolipoprotein E allele ε 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993;43:1467–1472.
- Notkola IL, Sulkava R, Pekkanen J, et al: Serum total cholesterol, apolipoprotein E ε 4 allele, and Alzheimer’s disease. Neuroepidemiology 1998;17:14–20.
- Wolozin B, Kellman W, Ruosseau P, et al: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439–1443.
- Jick H, Zornberg GL, Jick SS, et al: Statins and the risk of dementia. Lancet 2000;356:1627–1631.
- Wolozin B, Wang SW, Li NC, et al: Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 2007;5:20.
- Sparks DL, Kryscio RJ, Ssabbagh MN, et al: Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008;5:416–421.
- Shepherd J, Blauw GJ, Murphy MB, et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623–1697.
-
Pollen DA: Hannah’s Heirs. The Quest for the Genetic Origins of Alzheimer’s Disease. Oxford, Oxford University Press, 1993, pp 1–296.
- Lippa CF, Saunders AM, Smith TW, et al: Familial and sporadic Alzheimer’s disease: neuropathology cannot exclude a final common pathway. Neurology 1996;46:406–412.
- Hinerfeld DA, Moonis M, Swearer JM, et al: Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. Arch Neurol 2007;64:1672–1673.
- Moonis M, Swearer JM, Dayaw MP, et al: Familial Alzheimer disease: decreases in CSF Aβ42 levels precede cognitive decline. Neurology 2005;65:323–325.
- Dietschy JM, Turley SD: Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004;45:1375–1397.
- Dzeletovic S, Breuer O, Lund E, et al: Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem 1995;225:73–80.
- Simons M, Schwärzler F, Lütjohann D, et al: Treatment with simvastatin in normocholesterolemic patients with Alzheimer disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346–350.
- Fassbinder K, Stroick M, Bertsch T, et al: Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002;59:1257–1258.
- Höglund K, Thelen KM, Syversen S, et al: The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2005;19:256–265.
- Locatelli S, Lütjohann D, Schmidt HHJ, et al: Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia. Arch Neurol 2002;59:213–216.
- Vega GL, Weiner MF: Plasma 24S hydroxycholesterol response to statins in Alzheimer’s disease patients: effects of gender, CYP46, and ApoE polymorphisms. J Mol Neurosci 2007;33:51–55.
-
McLean RA, Sanders WL, Stroup WW: A unified approach to mixed linear models. Am Stat 1991;45:54–64.
External Resources
-
Singer JD, Willett JB: Applied Longitudinal Data Analysis. Modeling Change and Event Occurrence. Oxford, Oxford University Press, 2003.
-
Verbeke G, Molenberghs G: Linear Mixed Models for Longitudinal Data, ed 1. New York, Springer, 2000.
-
Draper NR, Smith HF: Applied Regression Analysis, ed 2. New York, Wiley & Sons, 1981.
- Ritchie K, Artero S, Touchon J: Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001;56:37–42.
- McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
- Riekse RG, Li G, Petrie EC, et al: Effect of statins on Alzheimer’s disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 2006;10:399–406.
- Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM: Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 2009;457:1128–1132.
- Vincent B, Cisse MA, Sunyach C, Guillot-Sestier MW, Cheller F: Regulation of βAPP and PrPc cleavage by α-secretase: mechanistic and therapeutic perspectives. Curr Alzheimer Res 2008;5:202–211.
- Cisse M, Mucke L: Alzheimer’s disease: a prion protein connection. Nature 2009;457:1090–1091.
Article / Publication Details
First-Page Preview
Accepted: July 03, 2009
Published online: May 29, 2009
Issue release date: July 2009
Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 2
ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)
For additional information: https://www.karger.com/DEM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
